Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer

Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer In vitro resistance modeling coupled with molecular analysis of autopsy tumor samples from patients with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer reveal novel biological insights into mechanisms of disease progression. These kinds of studies will facilitate the development of rationally targeted therapies in the era of genetically informed cancer medicine. Clin Cancer Res; 16(22); 5371–3. ©2010 AACR. Commentary on Suda et al., p. 5489 Received September 22, 2010. Accepted September 29, 2010. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Cancer Research American Association of Cancer Research

Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer

Clinical Cancer Research , Volume 16 (22): 5371 – Nov 15, 2010

Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer

Clinical Cancer Research , Volume 16 (22): 5371 – Nov 15, 2010

Abstract

In vitro resistance modeling coupled with molecular analysis of autopsy tumor samples from patients with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer reveal novel biological insights into mechanisms of disease progression. These kinds of studies will facilitate the development of rationally targeted therapies in the era of genetically informed cancer medicine. Clin Cancer Res; 16(22); 5371–3. ©2010 AACR. Commentary on Suda et al., p. 5489 Received September 22, 2010. Accepted September 29, 2010.

Loading next page...
 
/lp/american-association-of-cancer-research/highly-active-antitumor-therapy-haatt-for-epidermal-growth-factor-joB5xgNJbi

References (16)

Publisher
American Association of Cancer Research
Copyright
Copyright © 2010 American Association for Cancer Research
ISSN
1078-0432
eISSN
1557-3265
DOI
10.1158/1078-0432.CCR-10-2405
pmid
21062927
Publisher site
See Article on Publisher Site

Abstract

In vitro resistance modeling coupled with molecular analysis of autopsy tumor samples from patients with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer reveal novel biological insights into mechanisms of disease progression. These kinds of studies will facilitate the development of rationally targeted therapies in the era of genetically informed cancer medicine. Clin Cancer Res; 16(22); 5371–3. ©2010 AACR. Commentary on Suda et al., p. 5489 Received September 22, 2010. Accepted September 29, 2010.

Journal

Clinical Cancer ResearchAmerican Association of Cancer Research

Published: Nov 15, 2010

There are no references for this article.